期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗多发性骨髓瘤的应用进展 被引量：9

原文传递
导出
摘要 多发性骨髓瘤(MM)作为中老年常见的血液肿瘤之一,预后相对较差,常规化学疗法(化疗)疗效欠理想。硼替佐米作为一种新药,属于蛋白酶体抑制剂,通过全新的机制达到抗骨髓瘤的作用。国内外临床研究表明硼替佐米单药以及同常规化疗药物组成的联合化疗方案对初始治疗,以及复发难治的MM患者均有良好疗效。因此以硼替佐米为主的联合化疗方案已被美国国家综合癌症协作网推荐作为MM患者治疗的重要选择之一。现将硼替佐米在MM治疗上的进展作一综述。
作者 何东 牛挺
机构地区 四川大学华西医院血液科及血液学研究室 成都市第一人民医院血液科
出处 《华西医学》 CAS 2012年第2期197-202,共6页 West China Medical Journal
关键词 多发性骨髓瘤 硼替佐米 治疗
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献51

  • 1张晓辉（综述）,黄晓军（审校）.造血干细胞移植治疗多发性骨髓瘤的研究进展[J].国际输血及血液学杂志,2007,30(4):328-331. 被引量：2
  • 2Kenneth CA,Melissa A,William B,et al.NCCN clinical practice guidelines in oncology multiple myeloma version I[S].2011:17.
  • 3Reeder CB,Reece DE,Kukreti V,et al.Cyclophosphamide,bortezomib and dexamethasone induction for newly diagnosed multiple myeloma:high response rates in a phaseⅡclinical trial[J].Leukemia,2009,23(7):1337-1341.
  • 4Hideshima T,Miltiades C,Akiyama M,et a1.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J].Blood,2003,101(4):1530-1534.
  • 5Jullig M,Zhang WV,Ferreira A,et al.MG132induced apoptosis is associated with P53-independent induction of pro-apoptotic NOXA and transcriptional activity of beta-catenin[J].Apoptosis,2006,11(4):627-641.
  • 6Roccaro AM,Hideshima T,Raje N,et a1.Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelia1cells[J].Cancer Ras,2006,66(1):184-191.
  • 7National Comprehensive Cancer Net work(NCCN).NCCN c1inical practice guidelines in oncology TM multiple myeloma(V.3.2008).http//www.nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
  • 8National Comprehensive Cancer Net work(NCCN).NCCN clinical practice guidelines in oncology multiple myeloma(V.1.2011).http://www.nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
  • 9Jagannath S,Durie BG,Wolf J,et a1.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol,2005,129(6):776-783.
  • 10Harousseau JL,Attal M,Leleu X,et al.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:results of an IFM phaseⅡstudy[J].Haematologica,2006,91(11):1498-1505.

二级参考文献48

  • 1黄晓军.蛋白酶体抑制剂的发现和临床应用给我们带来了什么?[J].中国实用内科杂志：临床前沿版,2006,26(6):881-881. 被引量：1
  • 2ZHANG Xiao-hui HUANG Xiao-jun LIU Kai-yan XU Lan-ping LIU Dai-hong CHEN Huan CHEN Yu-hong WANG Jing-zhi HAN Wei LU Dao-pei.Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma[J].Chinese Medical Journal,2007(6):463-468. 被引量：7
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin,2007,57(1) :43-60.
  • 4Sirohi B, Powles R. Multiple myeloma. Lancet, 2004; 363 (9412) :875-887.
  • 5Durie BL, Harousseau JH, Miguel JS, et al. International uniform response criteria for multiple myeloma. Luekemia, 2006 , 20(9) : 1467-1473.
  • 6National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in OneologyTM Multiple Myeloma (V. 3. 2008). Available at http://www. nccn. org/ professionals/physician_gle/PDF/myeloma. pdf.
  • 7Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet,2006 367(9513) :825-831.
  • 8Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer,2004,4(5) :349-360.
  • 9Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasomc inhibitor PS-341. Blood, 2003 ,101 (4) : 1530-1534.
  • 10Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial ceils. Cancer Res, 2006 , 66 (1) : 184-191.

共引文献31

同被引文献62

  • 1陈海飞（综述）,侯健（审校）,王东星（审校）.血清游离轻链检测及其临床应用进展[J].国际输血及血液学杂志,2007,30(1):74-77. 被引量：8
  • 2孙江涛,孔立.一种硼替佐米的合成方法:中国,101812026[P].2010-08-25.(CA2010,153:383296)
  • 3李勇华,侯健.多发性骨髓瘤的发病机制[J].中国全科医学,2007,10(18):1492-1495. 被引量：17
  • 4Li YX, Plesescu M, Sheehan P. Synthesis of four iso- topically labeled forms fo a proteasome inhibitor, borte- zomib[J]. J Labelled Compd Radiopharm, 2007, 50(5- 6): 402-6.
  • 5Zhu YQ, Zhao X, Zhu XR, et al. Design, synthesis, biological evaluation, and structure-activity relationship (sar) discussion of dipeptidyl boronate proteasome in- hibitors, Part I : Comprehensive understanding of the SAR of r-amino acid boronates[J]. J Med Chem, 2009, 52(14): 4192-9.
  • 6Piekersgill IF, Bishop J, Koellner C, et al. Synthesis of boronic ester and acid compounds: WO2005097809[P]. 2005-10-20. (CA 2005, 143: 387386).
  • 7Beenen MA, An C, Ellman JA. Asymmetric coppercat- alyzed synthesis of c-amino boronate esters from N- tertbutanesulfinyl aldimines [J]. J Am Chem Soc, 2008, 130(22): 6910-1.
  • 8Venkata PR, Madinaguda MN, Hyderabad M, et al. Bortezomib and process for producing same: WO2009036281 [P]. 2009-03-19. (CA 2009, 150: 330133).
  • 9Ivanov AS, Zhalnina AA, Shishkov SV. A convergent approach to synthesis of vortezomib: the use of TBTU suppresses racemization in the fragment condensation[J]. Tetrahedron, 2009, 65(34): 7105-8.
  • 10ReikoWatanabe, Michihide Tokuhira, Masahiro Kiza- ki. Current approaches for the treatment of multiple myeloma[-Jl. International Journal of Hematology, 2013,21t973-973.

引证文献9

二级引证文献42

华西医学
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部